Authors: RUEDA F MARTI F PARDO N BADELL I PEIRO M BERTRAN E VILLEN E GARCIA J CUBELLS J

Citation: F. Rueda et al., INTERLEUKIN-2 IN NEUROBLASTOMA - CLINICAL PERSPECTIVES BASED ON BIOLOGICAL STUDIES, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 11(5), 1996, pp. 303-308

Authors: PARDO N MARTI F FRAGA G ILLA J BADELL I PEIRO M BERTRAN E GARCIA J RUEDA F CUBELLS J

Citation: N. Pardo et al., HIGH-DOSE SYSTEMIC INTERLEUKIN-2 THERAPY IN STAGE-IV NEUROBLASTOMA FOR ONE-YEAR AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION - PILOT-STUDY, Medical and pediatric oncology, 27(6), 1996, pp. 534-539

Authors: MARTI F MUNOZ J PEIRO M BERTRAN E FERRAN C OCTAVIO C GARCIA J RUEDA F

Citation: F. Marti et al., HIGHER CYTOTOXIC ACTIVITY AND INCREASED LEVELS OF IL-1-BETA, IL-6, AND TNF-ALPHA IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS, American journal of hematology, 49(3), 1995, pp. 237-239

Authors: MARTI F PARDO N PEIRO M BERTRAN E AMILL B GARCIA J CUBELLS J RUEDA F

Citation: F. Marti et al., PROGRESSION OF NATURAL IMMUNITY DURING ONE-YEAR TREATMENT OF RESIDUALDISEASE IN NEUROBLASTOMA PATIENTS WITH HIGH-DOSES OF INTERLEUKIN-2 AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION, Experimental hematology, 23(14), 1995, pp. 1445-1452

Authors: MARTI F PETRIZ J PEIRO M AMILL B BERTRAN E TUGUES D SANCHEZ T RUEDA F GARCIA J

Citation: F. Marti et al., FUNCTIONAL AND PHENOTYPE COMPARATIVE-STUDY BETWEEN NATURAL-KILLER ANDINTERLEUKIN-2-ACTIVATED KILLER CYTOTOXICITIES FROM ELUTRIATION SAMPLES, Experimental hematology, 21(8), 1993, pp. 1119-1119

Authors: MARTI F MIRALLES A PEIRO M AMILL B DEDALMASES C PINOL G RUEDA F GARCIA J

Citation: F. Marti et al., DIFFERENTIAL EFFECT OF CRYOPRESERVATION ON NATURAL-KILLER-CELL AND LYMPHOKINE-ACTIVATED KILLER-CELL ACTIVITIES, Transfusion, 33(8), 1993, pp. 651-655